abi-h0731
mAbexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02908191)
Timeline
Indications
Studied for
Mechanism of action
- P-selectin glycoprotein ligand 1INHIBITOR
SELPLG inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- abi-h0731
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04820686 | Phase 2 | May 7, 2021 | Arbutus Biopharma Corporation, Assembly Biosciences |
| NCT04781647 | Phase 2 | Feb 18, 2021 | Assembly Biosciences |
| NCT04454567 | Phase 2 | Nov 11, 2020 | Assembly Biosciences |
| NCT03780543 | Phase 2 | Dec 20, 2018 | Assembly Biosciences |
| NCT03577171 | Phase 2 | Jun 19, 2018 | Assembly Biosciences |
| NCT03576066 | Phase 2 | Jun 11, 2018 | Assembly Biosciences |
| NCT03109730 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Assembly Biosciences |
| NCT02908191 | Phase 1 | Nov 1, 2016 | Assembly Biosciences |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assembly Biosciences | For profit | 8 | 8 | 2 | 2016 |
| Arbutus Biopharma Corporation | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1